Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo

Inhibition of proteasome-associated deubiquitinases (DUBs) is emerging as a novel strategy for cancer therapy. It was recently reported that auranofin (Aur), a gold (I)-containing compound used clinically to treat rheumatoid arthritis, is a proteasome-associated DUB inhibitor. Disulfiram (DSF), an i...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Huang, Hongbiao, Liao, Yuning, Liu, Ningning, Hua, Xianliang, Cai, Jianyu, Yang, Changshan, Long, Huidan, Zhao, Chong, Chen, Xin, Lan, Xiaoying, Zang, Dan, Wu, Jinjie, Li, Xiaofen, Shi, Xianping, Wang, Xuejun, Liu, Jinbao
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2015
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4823072/
https://ncbi.nlm.nih.gov/pubmed/26625200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.6425
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak